BR112016026443A2 - compostos heterocíclicos deuterados, seus usos, e composição farmacêutica - Google Patents

compostos heterocíclicos deuterados, seus usos, e composição farmacêutica

Info

Publication number
BR112016026443A2
BR112016026443A2 BR112016026443A BR112016026443A BR112016026443A2 BR 112016026443 A2 BR112016026443 A2 BR 112016026443A2 BR 112016026443 A BR112016026443 A BR 112016026443A BR 112016026443 A BR112016026443 A BR 112016026443A BR 112016026443 A2 BR112016026443 A2 BR 112016026443A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
heterocyclic compounds
deuterated
deuterated heterocyclic
compounds
Prior art date
Application number
BR112016026443A
Other languages
English (en)
Other versions
BR112016026443A8 (pt
BR112016026443B1 (pt
Inventor
Jan Marik
Joseph P Lyssikatos
Simon Williams
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112016026443A2 publication Critical patent/BR112016026443A2/pt
Publication of BR112016026443A8 publication Critical patent/BR112016026443A8/pt
Publication of BR112016026443B1 publication Critical patent/BR112016026443B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled
BR112016026443-6A 2014-05-13 2015-05-12 Compostos heterocíclicos deuterados, seus usos, e composição farmacêutica BR112016026443B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461992717P 2014-05-13 2014-05-13
US61/992,717 2014-05-13
PCT/EP2015/060447 WO2015173225A1 (en) 2014-05-13 2015-05-12 Deuterated heterocyclic compounds and their use as imaging agents

Publications (3)

Publication Number Publication Date
BR112016026443A2 true BR112016026443A2 (pt) 2017-08-15
BR112016026443A8 BR112016026443A8 (pt) 2021-07-06
BR112016026443B1 BR112016026443B1 (pt) 2023-07-04

Family

ID=

Also Published As

Publication number Publication date
CA2948721C (en) 2023-03-28
ES2867814T3 (es) 2021-10-20
JP2017515856A (ja) 2017-06-15
US20190201561A1 (en) 2019-07-04
NZ726208A (en) 2023-11-24
EP3143011B1 (en) 2021-03-03
LT3143011T (lt) 2021-05-10
NZ764181A (en) 2023-11-24
AU2019203369A1 (en) 2019-06-06
HRP20210641T1 (hr) 2021-05-28
IL248692A0 (en) 2017-01-31
RU2696492C2 (ru) 2019-08-02
SG10201805628TA (en) 2018-08-30
HUE053939T2 (hu) 2021-08-30
RS61810B1 (sr) 2021-06-30
EP3901145A1 (en) 2021-10-27
SI3143011T1 (sl) 2021-08-31
DK3143011T3 (da) 2021-05-03
US20200297875A1 (en) 2020-09-24
US10076581B2 (en) 2018-09-18
IL271631A (en) 2020-02-27
KR102618139B1 (ko) 2023-12-27
MX2016014615A (es) 2017-03-06
KR20170002639A (ko) 2017-01-06
IL280791A (en) 2021-04-29
IL280791B2 (en) 2024-03-01
CN106459059A (zh) 2017-02-22
KR20230035445A (ko) 2023-03-13
AU2019203369B2 (en) 2020-06-04
MX2020010847A (es) 2021-07-16
CN110483522A (zh) 2019-11-22
JP6529986B2 (ja) 2019-06-12
CN106459059B (zh) 2019-09-24
IL271631B (en) 2021-05-31
JP6681498B2 (ja) 2020-04-15
AU2015261008A1 (en) 2016-11-17
US20230218782A1 (en) 2023-07-13
US11504440B2 (en) 2022-11-22
SG11201609281UA (en) 2016-12-29
KR102530129B1 (ko) 2023-05-10
BR112016026443A8 (pt) 2021-07-06
CA2948721A1 (en) 2015-11-19
WO2015173225A1 (en) 2015-11-19
IL248692B (en) 2020-01-30
RU2016147742A3 (pt) 2018-10-08
JP2019147825A (ja) 2019-09-05
EP3143011A1 (en) 2017-03-22
PL3143011T3 (pl) 2021-07-19
RU2016147742A (ru) 2018-06-18
CN110483522B (zh) 2022-05-03
IL280791B1 (en) 2023-11-01
US20160250358A1 (en) 2016-09-01
US10675367B2 (en) 2020-06-09
PT3143011T (pt) 2021-04-26
AU2015261008B2 (en) 2019-02-14

Similar Documents

Publication Publication Date Title
BR112016030787A2 (pt) entidade química, composição farmacêutica e seu uso
BR112016016158A2 (pt) Derivados de heterociclila bicíclicos como inibidores de irak4, sua composição farmacêutica e seus usos
CL2016002569A1 (es) Anticuerpos, composiciones farmacéuticas y usos de los mismos
BR112016023422A2 (pt) Dispersão seca por spray, composição farmacêutica e seus usos, kit e comprimido
BR112017004612A2 (pt) compostos, composição farmacêutica, usos de um composto, e kit
BR112016027722A2 (pt) compostos contendo grupo autoimulativo e seu uso
IL247062A0 (en) Heterocyclic compounds, their preparation and pharmaceutical preparations containing them
BR112016015706A2 (pt) composto, uso do mesmo e composição farmacêutica
BR112016018062A2 (pt) compostos terapêuticos, composição farmacêutica e usos
DK3297605T3 (da) Topiske, farmaceutiske sammesætninger
DK3229810T3 (da) Phospholipid-ether-analoger som kræftrammende lægemiddelvehikler
DK3143011T3 (da) Deutererede heterocykliske forbindelser og deres anvendelse som billeddannende stoffer
BR112016023628A2 (pt) composições farmacêuticas.
BR112016023341A2 (pt) composição desinfetante de ação rápida
DK3089741T3 (da) Farmaceutiske sammensætninger omfattende azd9291
BR112016026879A2 (pt) Composição farmacêutica líquida
BR112016025659A2 (pt) compostos, seus usos, e composições farmacêuticas para induzir condrogênese
BR112016024298A2 (pt) compostos de quinoxalina e seus usos.
DK3532029T3 (da) Flydende farmaceutisk sammensætning
DK3223796T3 (da) Farmaceutiske sammensætninger, fremstilling og anvendelser deraf
DK3554534T3 (da) Farmaceutisk sammensætning omfattende insulin
DK3199161T3 (da) Farmaceutisk præparat
BR112016026552A2 (pt) derivados de carboxamida, seus usos, composição farmacêutica, e combinação
BR112017013012A2 (pt) compostos de indenil, composições farmacêuticas e usos médicos destes
DK3278801T3 (da) Farmaceutisk sammensætning indeholdende mirabegron

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/05/2015, OBSERVADAS AS CONDICOES LEGAIS